



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: PRESTA ET AL. Examiner: UNKNOWN
Serial No.: 10/027,736 Group Art Unit: UNKNOWN
Filed: DECEMBER 19, 2001 Docket: 11669.92US01
Confirmation No.: 9756
Title: NON-HUMAN Fc RECEPTORS AND METHODS OF USE

RECEIVED

APR 15 2002

TECH CENTER 1600/2900

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence and the paper(s), as described herein, are being deposited in the United States Postal Service, as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on April 8, 2002.

By: Sheryl A. Boerboom
Sheryl A. Boerboom

Commissioner for Patents
Washington, D.C. 20231

Sir:

We are transmitting herewith the attached:

- ☒ Transmittal Sheet in duplicate containing Certificate of Mailing
- ☒ Supplemental Information Disclosure Statement, Form 1449, 36 References
- ☒ Return postcard

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers or any future reply, if appropriate. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. A duplicate of this sheet is enclosed.

MERCHANT & GOULD P.C.
P.O. Box 2903, Minneapolis, MN 55402-0903
612.332.5300

By: Katherine M. Kowalchuk
Name: Katherine M. Kowalchuk
Reg. No.: 36,848
KKowalchuk:sab





IN 10/027,736

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

RECEIVED

Applicant: PRESTA ET AL. Examiner: UNKNOWN
Serial No.: 10/027,736 Group Art Unit: UNKNOWN
Filed: DECEMBER 19, 2001 Docket No.: 11669.92US01
Title: NON-HUMAN Fc RECEPTORS AND METHODS OF USE

APR 15 2002

TECH CENTER 1600/290

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence and the paper(s), as described herein, are being deposited in the United States Postal Service, as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on April 8, 2002.

By:

Sheryl A. Boerboom

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b))

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted before the mailing date of a first Office Action on-the-merits. Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. §1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.



Please charge any additional fees or credit any overpayment to Deposit Account No. 13-

2725.

Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300

Date: April 8, 2002

Katherine M. Kowalchuk
Katherine M. Kowalchuk
Reg. No. 36,848
KMK:sab



RECEIVED

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 11669.92US01	Application Number: 10/027,736
	Applicant: PRESTA ET AL.	
	Filing Date: 12/19/01	Group Art Unit: UNKNOWN

APR 15 2002
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Benincosa, L. et al., "Pharmacokinetics and Pharmacodynamics of a Humanized Monoclonal Antibody to Factor IX in Cynomolgus Monkeys", <i>The Journal of Pharmacology and Experimental Therapeutics</i> , Vol. 292, No. 2, pp. 810-816 (February 2000)
	Brok, H. et al., "Prophylactic and therapeutic effects of a humanized monoclonal antibody against the IL-2 receptor (DACLIZUMAB) on collagen-induced arthritis (CIA) in rhesus monkeys", <i>Clinical and Experimental Immunology</i> , 124:134-141 (2001)
	Clynes, R. et al., "Fc receptors are required in passive and active immunity to melanoma", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 95, No. 2, pp. 652-656 (January 20, 1998)
	Fishwild, D. et al., "Differential Effects of Administration of a Human Anti-CD4 Monoclonal Antibody, HM6G, in Nonhuman Primates", <i>Clinical Immunology</i> , Vol. 92, No. 2, pp. 138-152 (1999)
	Ghetie, V. et al., "Multiple Roles for the Major Histocompatibility Complex Class I-Related Receptor FcRn", <i>Annual Review of Immunology</i> , 18:739-766 (2000)
	Glennie, M. et al., "Clinical trials of antibody therapy", <i>Immunology Today</i> , Vol. 21, No. 8, pp. 403-411 (August 2000)
	Gobburu, J. et al., "Pharmacokinetics/Dynamics of 5c8, a Monoclonal Antibody to CD154 (CD40 Ligand) Suppression of an Immune Response in Monkeys", <i>The Journal of Pharmacology and Experimental Therapeutics</i> , Vol. 286, No. 2, pp. 925-930 (1998)
	Hamawy, M. et al., "Immunotoxin FN18-CRM9 Induces Stronger T Cell Signaling Than Unconjugated Monoclonal Antibody FN18", <i>Transplantation</i> , Vol. 72, No. 3, pp. 496-503 (August 15, 2001)
	Hart, T. et al., "Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys", <i>The Journal of Allergy and Clinical Immunology</i> , Vol. 108, No. 2, pp. 250-257 (August 2001)
	Kao, F. et al., "Genetics of Somatic Mammalian Cells, VII. Induction and Isolation of Nutritional Mutants in Chinese Hamster Cells", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 60, No. 4, pp. 1275-1281 (August 1968)
	Kim, J. et al., "Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn", <i>European Journal of Immunology</i> , 29:2819-2825 (1999)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

RECEIVED

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 11669.92US01	Application Number: 10/027,736
	Applicant: PRESTA ET AL.	
	Filing Date: 12/19/01	Group Art Unit: UNKNOWN

	Küester, H. et al., "Characterization and Expression of the Gene for the Human Fc Receptor γ Subunit", <i>The Journal of Biological Chemistry</i> , Vol. 265, No. 11, pp. 6448-6452 (April 15, 1990)
	Kurucz, I. et al., "Bacterially expressed human Fc γ RIIb is soluble and functionally active after in vitro refolding", <i>Immunology Letters</i> , 75:33-40 (2000)
	Lehrnbecher, T. et al., "Variant Genotypes of the Low-Affinity Fc γ Receptors in Two Control Populations and a Review of Low-Affinity Fc γ Receptor Polymorphisms in Control and Disease Populations", <i>Blood</i> , Vol. 94, No. 12, pp. 4220-4232 (December 15, 1999)
	Lin, Y. et al., "Preclinical Pharmacokinetics, Interspecies Scaling, and Tissue Distribution of a Humanized Monoclonal Antibody against Vascular Endothelial Growth Factors", <i>The Journal of Pharmacology and Experimental Therapeutics</i> , Vol. 288, No. 1, pp. 371-378 (1999)
	Maxwell, K. et al., "Crystal structure of the human leukocyte Fc receptor, Fc γ RIIa", <i>Nature Structural Biology</i> , Vol. 6, No. 5, pp. 437-442 (May 1999)
	Mihara, M. et al., "Humanized Antibody to Human Interleukin-6 Receptor Inhibits the Development of Collagen Arthritis in Cynomolgus Monkeys", <i>Clinical Immunology</i> , Vol. 98, No. 3, pp. 319-326 (March 2001)
	Mordenti, J. et al., "Comparisons of the Intraocular Tissue Distribution, Pharmacokinetics, and Safety of 125 I-Labeled Full-Length and Fab Antibodies in Rhesus Monkeys Following Intravitreal Administration", <i>Toxicologic Pathology</i> , Vol. 27, No. 5, pp. 536-544 (September-October 1999)
	Mourad, G. et al., "Humanized IgG1 and IgG4 Anti-CD4 Monoclonal Antibodies", <i>Transplantation</i> , Vol. 65, No. 5, pp. 632-641 (March 15, 1998)
	Ory, P. et al., "Characterization of Polymorphic Forms of Fc Receptor III on Human Neutrophils", <i>The Journal of Clinical Investigation</i> , Vol. 83, No. 5, pp. 1676-1681 (May 1989)
	Ory, P. et al., "Sequences of Complementary DNAs that Encode the NA1 and NA2 Forms of Fc Receptor III on Human Neutrophils", <i>The Journal of Clinical Investigation</i> , Vol. 84, No. 5, pp. 1688-1691 (November 1989)
	Poston, R. et al., "Effects of Humanized Monoclonal Antibody to Rhesus CD11a in Rhesus Monkey Cardiac Allograft Recipients", <i>Transplantation</i> , Vol. 69, No. 10, pp. 2005-2013 (May 27, 2000)
	Radaev, S. et al., "The Structure of a Human Type III Fc γ Receptor in Complex with Fc", <i>The Journal of Biological Chemistry</i> , Vol. 276, No. 19, pp. 16469-16477 (May 11, 2001)
	Ravetch, J. et al., "IgG Fc Receptors", <i>Annual Review of Immunology</i> , Vol. 19:275-290 (2001)
	Reichert, J., "Monoclonal antibodies in the clinic", <i>Nature Biotechnology</i> , Vol. 19, No. 9, pp. 819-822 (September 2001)
	Richter, W. et al., "Animal Pharmacokinetics of the Tumor Necrosis Factor Receptor-Immunoglobulin Fusion Protein Lenercept and Their Extrapolation to Humans", <i>Drug Metabolism and Disposition</i> , Vol. 27, No. 1, pp. 21-25 (January 1999)
	Sampson, J. et al., "Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors", <i>PNAS</i> , Vol. 97, No. 13, pp. 7503-7508 (June 20, 2000)
	Sautès, C., "Structure and Expression of Fc Receptors (FcR)", <i>Cell-Mediated Effects of Immunoglobulins</i> , Chap. 2, pp. 29-66 (1997)
	Schuurman, J. et al., "The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds", <i>Molecular Immunology</i> , Vol. 38, No. 1, pp. 1-8 (January 2001)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

RECEIVED

FORM 1449*

INFORMATION DISCLOSURE STATEMENT

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number:

11669.92US01

Application Number:

10/027,736


APR 15 2002

Applicant: PRESTA ET AL.

TECH CENTER 1600/2900

Filing Date: 12/19/01

Group Art Unit: UNKNOWN



	Shinkura, H. et al., "Safety and kinetic properties of a humanized antibody to human interleukin-6 receptor in healthy non-human primates", <i>Toxicology</i> , 122:163-170 (October 19, 1997)
	Sondermann, P. et al., "Crystal structure of the soluble form of the human Fcγ-receptor IIb: a new member of the immunoglobulin superfamily at 1.7 Å resolution", <i>The EMBO Journal</i> , Vol. 18, No. 5, pp. 1095-1103 (March 1, 1999)
	Sondermann, P. et al., "The 3.2-Å crystal structure of the human IgG1 Fc fragment-FcγRIII complex", <i>Nature</i> , 406:267-273 (July 20, 2000)
	Spiegelberg, H., "Biological Activities of Immunoglobulins of Different Classes and Subclasses", <i>Advances in Immunology</i> , 19:259-294 (1974)
	van der Pol, W. et al., "IgG receptor IIa alleles determine susceptibility and severity of Guillain-Barré syndrome", <i>Neurology</i> , Vol. 54, No. 8, pp. 1661-1665 (April 25, 2000)
	van Dijk, M. et al., "Human antibodies as next generation therapeutics", <i>Current Opinion in Chemical Biology</i> , 5:368-374 (2001)
	Waurzyniak, B. et al., "In Vivo Toxicity, Pharmacokinetics, and Antileukemic Activity of TXU (Anti-CD7)-Pokeweed Antiviral Protein Immunotoxin", <i>Clinical Cancer Research</i> , Vol. 3, No. 6, pp. 881-890 (June 1997)



23552

PATENT TRADEMARK OFFICE

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.